Apoptosis, proliferation, and Fas (APO-I, CD95)/Fas ligand expression in medullary carcinoma of the breast

被引:0
|
作者
Yakirevich, E
Maroun, L
Cohen, O
Izhak, OB
Rennert, G
Resnick, MB
机构
[1] Lady Davis Carmel Med Ctr, Dept Pathol, IL-34362 Haifa, Israel
[2] Rambam Med Hosp, Dept Pathol, Haifa, Israel
[3] Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel
[4] Lady Davis Carmel Med Ctr, Dept Surg, IL-34362 Haifa, Israel
[5] Lady Davis Carmel Med Ctr, Dept Community Med & Epidemiol, IL-34362 Haifa, Israel
来源
JOURNAL OF PATHOLOGY | 2000年 / 192卷 / 02期
关键词
breast; medullary carcinoma; apoptosis; TUNEL; proliferation; PCNA; Fas; FasL;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Medullary carcinoma (MC) of the breast is a unique subtype of infiltrating ductal carcinoma that is characterized by a prominent lymphoid infiltrate and improved prognosis. Activated granzyme B+/CD8(+) cytotoxic T-lymphocytes (CTLs) infiltrating tumour cell nests constitute a major subset within the lymphoid infiltrate. As CTLs destroy target tumour cells by triggering apoptosis, it mould be of interest to determine whether the apoptotic rate in MC is increased. This study evaluates the extent of apoptosis in relation to Fas (APO-1, CD95)/Fas ligand (FasL) expression in MC. Fourteen cases of typical MC (TMC) and 15 cases of atypical MC (AMC) classified according to the Ridolfi criteria, as well as 19 cases of poorly differentiated infiltrating ductal carcinoma (PDC) were evaluated. The apoptotic index (AI) was assessed by the TUNEL method on paraffin-embedded tissue. Cell proliferation was evaluated immunohistochemically by PCNA staining. The level of Fas/FasL expression was determined semiquantitatively by immunohistochemistry using a four-grade scoring system. The AI was significantly increased in TMC and AMC as opposed to the PDC subgroup (2.2 +/- 0.8, 2.1 +/- 0.8, and 1.3 +/- 0.6, respectively; p < 0.05). A significant proportion (31.8 +/- 7.9% in TMC and 25.8 +/- 9.7% in AMC) of the apoptotic tumour cells within tumour nests mere in close contact with CD3(+) lymphocytes. Increased apoptosis was not accompanied by increased proliferation of tumour cells. The extent of Fas expression did not differ between the three subgroups. FasL was expressed both by tumour infiltrating lymphocytes in MC and by tumour epithelium in all three subgroups. The observation that the majority of MCs express Fas and are infiltrated by lymphocytes expressing FasL suggests that increased apoptosis in MC is mediated by Fas/FasL. However, our observation that the majority of MCs also express Fast and the fact that tumours co-expressing Fas and FasL did not show increased apoptosis suggest that there may be additional cytotoxic pathways that lead to tumour apoptosis in MC. Copyright (C) 2000 John Wiley & Sons, Ltd.
引用
收藏
页码:166 / 173
页数:8
相关论文
共 50 条
  • [41] Co-expression of Fas (APO-1, CD95)/Fas ligand by BeWo and NJG choriocarcinoma cell lines
    Rajashekhar, G
    Loganath, A
    Roy, AC
    Mongelli, JM
    GYNECOLOGIC ONCOLOGY, 2003, 91 (01) : 101 - 111
  • [42] Inhibition of Fas (CD95) expression and Fas-mediated apoptosis by oncogenic Ras
    Fenton, RG
    Hixon, JA
    Wright, PW
    Brooks, AD
    Sayers, TJ
    CANCER RESEARCH, 1998, 58 (15) : 3391 - 3400
  • [43] Anti-Fas (CD95/Apo-I) autoantibodies and soluble Fas levels concur in T cell depletion in HIV type 1 infection
    Silvestris, F
    Grinello, D
    Del Prete, A
    Cafforio, P
    Quarto, M
    Dammacco, F
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2001, 17 (07) : 603 - 614
  • [44] Expression of fas (CD95/APO-1) ligand by human breast cancers: Significance for tumor immune privilege
    O'Connell, J
    Bennett, MW
    O'Sullivan, GC
    O'Callaghan, J
    Collins, JK
    Shanahan, F
    CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 1999, 6 (04) : 457 - 463
  • [45] Posttranscriptional control of the apoptosis-inducing Fas (CD95) ligand
    Brunner, T
    TISSUE ANTIGENS, 2004, 64 (04): : 341 - 341
  • [46] CD95/Fas ligand induced toxicity
    Haluck-Kangas, Ashley
    Peter, Marcus E.
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2023, 51 (01) : 21 - 29
  • [47] REGULATION OF CELL-SURFACE APO-1/FAS (CD95) LIGAND EXPRESSION BY METALLOPROTEASES
    MARIANI, SM
    MATIBA, B
    BAUMLER, C
    KRAMMER, PH
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (08) : 2303 - 2307
  • [48] Expression of the Fas/APO-1/CD95 antigen mediating apoptosis in human leukemic cells
    Shishkin, YV
    Sedyakhina, NP
    Zabotina, TN
    Kuznetsov, SV
    Turkina, AG
    Palkina, TN
    Polosukhina, ER
    Shirin, AD
    Volkova, MA
    Frenkel, MA
    Khoroshko, ND
    Kadagidze, ZG
    Baryshnikov, AY
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 1996, 122 (11) : 1122 - 1124
  • [49] Fas antigen/APO-1 (CD95) expression on myeloma cells
    Shima, Y
    Nishimoto, N
    Yoshizaki, K
    Kishimoto, T
    LEUKEMIA & LYMPHOMA, 1996, 23 (5-6) : 521 - +
  • [50] Expression of Fas (CD95) and Fas-ligand in normal and tumorous human thyroid tissues
    Fantus, D
    Ezzat, S
    Asa, SL
    MODERN PATHOLOGY, 1998, 11 (01) : 56A - 56A